Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protalix BioTherapeuticsPLX +2.18%54 Cash-to-Debt is 4.42 as of Jun. 2026, which is 375% above its 10-year median of 0.93. GuruFocus rates PLX with a GF Score™ of 54/100 and a GF Value™ of $2.21 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,399 Biotechnology companies, Protalix BioTherapeutics ranks worse than 55.54% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Protalix BioTherapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 4.42.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Protalix BioTherapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Protalix BioTherapeutics's Cash-to-Debt or its related term are showing as below:
PLX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29 Med: 0.93 Max: 6.64
Current: 4.42
During the past 13 years, Protalix BioTherapeutics's highest Cash to Debt Ratio was 6.64. The lowest was 0.29. And the median was 0.93.
PLX's Cash-to-Debt is ranked worse than 55.54% of 1399
companies
in the Biotechnology industry
Industry Median: 6.49
vs PLX: 4.42
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Protalix BioTherapeutics Cash-to-Debt Related Terms
Protalix BioTherapeutics Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Protalix BioTherapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protalix BioTherapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics (PLX) has a Cash-to-Debt of 4.42 as of Jun. 2026. This is 375% above median its historical median of 0.93. Over the past decade, Protalix BioTherapeutics' Cash-to-Debt has ranged from 0.29 to 6.64. According to the industry distribution chart, Protalix BioTherapeutics ranks #777 out of 1399 companies in the Biotechnology industry, placing it in the top 55.5%.
Is Protalix BioTherapeutics' Cash-to-Debt too high?
Protalix BioTherapeutics' current Cash-to-Debt of 4.42 is 375% above median its 10-year median of 0.93. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 6.64. The Biotechnology industry median Cash-to-Debt is 6.49. Protalix BioTherapeutics' value of 4.42 is 31.9% below this industry median. Based on the distribution chart, Protalix BioTherapeutics ranks #777 out of 1399 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Protalix BioTherapeutics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Cash-to-Debt compare to GLSI and DTIL?
According to the Biotechnology industry distribution chart, Protalix BioTherapeutics ranks #777 out of 1399 companies for Cash-to-Debt. This places Protalix BioTherapeutics in the lower half of its industry. The industry median Cash-to-Debt is 6.49. Protalix BioTherapeutics' value of 4.42 is 31.9% below this benchmark. Historically, Protalix BioTherapeutics' own Cash-to-Debt has ranged from 0.29 to 6.64 over the past decade. While the company's 10-year median is 0.93 vs. the industry median of 6.49, Protalix BioTherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.49, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protalix BioTherapeutics's current Cash-to-Debt of 4.42 is 31.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protalix BioTherapeutics's current Cash-to-Debt is 4.42, which is 375% above median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (PLX) is currently considered Fairly Valued. The stock's GF Value™ is $2.21, compared to a current price of $2.34 — trading 5.9% above its estimated fair value. The current Cash-to-Debt is 4.42, which is 375% above median its 10-year median of 0.93 and 31.9% below the Biotechnology industry median of 6.49. Protalix BioTherapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Protalix BioTherapeutics (PLX), the current Cash-to-Debt is 4.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protalix BioTherapeutics (PLX) Overvalued in 2026?
Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued.
The current stock price of $2.34 is trading 5.9% above its estimated GF Value™ of $2.21.
GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.
Key valuation signals for PLX:
Cash-to-Debt: 4.42 (375% above median its 10-year median of 0.93)
GF Value™: $2.21 vs. price of $2.34 (5.9% above fair value)
Industry Position: 31.9% below the Biotechnology median (#777 of 1399)
No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
54GF Score
Get the complete analysis for PLX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLX has been successfully added to your 
